4 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 1 | Terminated 1 |
Follow Craniofacial Abnormalities: new trials by email Literature Review of Craniofacial Abnormalities trials Research Report on Craniofacial Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors TNO155, TNO155 in combination with EGF816 (nazartinib) - Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC | Phase 1 | Terminated | Novartis Pharmaceuticals | 227 | 2017-05-26 | 2026-07-09 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies INCB062079 - Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | Phase 1 | Terminated | Incyte Corporation | 25 | 2017-05-25 | 2025-10-21 |
| Serum-Free Thymus Transplantation in DiGeorge Anomaly Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression - DiGeorge Anomaly | Phase 1 | Terminated | Sumitomo Pharma Switzerland GmbH | 2 | 2008-04-01 | 2022-04-01 |
Acrocephalosyndactylia (2) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · DiGeorge Syndrome (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Immunologic Deficiency Syndromes (1) · Melanoma (1) · Nasopharyngeal Neoplasms (1) · Noonan Syndrome (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thymic aplasia (1)
Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Musculoskeletal Abnormalities (4) · Musculoskeletal Diseases (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Bone Diseases (2) · Bone Diseases, Developmental (2) · Carcinoma (2) · Cardiovascular Abnormalities (2)
Immunosuppression Therapy (1) · derazantinib (1) · nazartinib (1)
Basilea Pharmaceutica (1) · Incyte Corporation (1) · Novartis Pharmaceuticals (1) · Sumitomo Pharma Switzerland GmbH (1)
United States (3) · Belgium (2) · Italy (2) · South Korea (2) · Spain (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Poland (1)
Luis F. Vinas, MD (1) · M. Louise Markert, M.D., Ph.D (1)
2017 (1), 2023 (1), K12HD043494 (1), R01AI047040 (1), R01AI054843 (1)